Chapter 5 A serum protein classifier identifying patients with advanced non-small cell lung cancer who derive clinical benefit from treatment with immune checkpoint inhibitors Mirte Muller1*, Karlijn Hummelink2*, Daniel Hurkmans3 , Anna-Larissa Niemeijer4, Kim Monkhorst2, Joanna Roder5 , Carlos Oliveira5 , Heinrich Roder5, Joachim G. Aerts3#, Egbert F. Smit1#. * These authors contributed equally as first-author #These authors jointly supervised this work 1Department of Thoracic Oncology, 2Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands, 3Department of Pulmonary Diseases, Erasmus Medical Center, Rotterdam, The Netherlands, 4Department of Pulmonary Diseases, Vrije Universiteit VU Medical Center, Amsterdam, The Netherlands, 5Biodesix, Boulder, Colorado. Clinical Cancer Research, 2020
RkJQdWJsaXNoZXIy MTk4NDMw